$6.44
arrow_drop_up1.41%Key Stats | |
---|---|
Open | $6.36 |
Prev. Close | $6.38 |
EPS | -4.01 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $233.37M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 6.24 | 6.73 |
52 Week Range | 3.61 | 22.74 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -4.01 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities ... - GlobeNewswire
This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)